Breaking News

Antares Earns Second OTREXUP Milestone

By Kristin Brooks | March 12, 2014

LEO Pharma launches psoriasis drug

Antares Pharma, Inc. has received a second $5 million milestone payment from LEO Pharma in connection with the launch of OTREXUP. In November 2013, the companies entered an exclusive license and promotion agreement for OTREXUP (methotrexate) for symptomatic control of severe recalcitrant psoriasis in adults, under which Antares is eligible to receive as much as $20 million in milestone payments. LEO Pharma is responsible for all promotion and marketing costs in dermatology. 
 
“We are excited that our partnership with LEO Pharma continues to evolve quickly,” said Paul Wotton, Ph.D., president and chief executive officer of Antares Pharma. “In just four short months since the approval of OTREXUP, our collaboration has achieved a second significant milestone while still very early in the rheumatoid arthritis launch phase. We look forward to a successful launch of OTREXUP for the psoriasis indication, and the expertise LEO’s dedicated U.S. sales force of 75 representatives will bring to the overall commercialization plan.”

Related Contract Manufacturing:

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems